Veterans Participate in Groundbreaking Alcohol Addiction Study
Hundreds of veterans will take part in a national clinical trial to assess the effectiveness of semaglutide in treating alcohol addiction. This trial was announced by the Department of Veterans Affairs (VA), responding to a prevalent health challenge in the veteran community. According to VA data, over 400,000 veterans nationwide have been diagnosed with alcohol use disorder (AUD).
The study, known as the Cessation or Reduction of Alcohol Consumption in Veterans trial, aims to explore the potential impact of GLP-1 receptor agonists on addictive behaviors. These medications are designed to mimic naturally occurring hormones that manage blood sugar, appetite, and brain reward pathways.
“This clinical trial reflects medical research that VA is uniquely situated to launch, and is aimed directly at benefitting Veterans,” stated VA Secretary Doug Collins. “By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery.”
How the VA Alcohol Use Disorder Trial Operates
More than 600 veterans will participate across 18 VA medical centers in the United States. These trials are essential for verifying treatment efficacy within specific groups while ensuring rigorous monitoring of safety and side effects.
- Participants’ Criteria: Individuals eligible for the trial are those between 18 and 80 years old, diagnosed with moderate or severe AUD.
- Evaluation Metrics: Participants will receive weekly injections of semaglutide or a placebo for 24 weeks, followed by a safety follow-up.
- Timeline: Recruitment began on July 28, with researchers observing drinking habits, health, and life quality improvements.
For participation information, veterans are encouraged to contact their local VA medical center or visit ClinicalTrials.gov to search for the trial.
The Need for a Controlled Trial
The trial was initiated following an observational study of veterans with Type 2 diabetes. Findings suggested patients prescribed GLP-1 medications showed lower rates of alcohol and substance use disorders compared to peers using other treatments. Additionally, GLP-1 usage correlated with reduced emergency visits and hospitalizations among those with pre-existing substance issues. However, as these associations do not confirm causality, a controlled trial is necessary to test semaglutide’s efficacy.
The VA advises against self-medicating with GLP-1 drugs or replacing established AUD treatments without consulting healthcare providers.
Participating VA Medical Centers
- Ann Arbor VA Health Care System — Ann Arbor, Michigan
- Charles George VA Medical Center — Asheville, North Carolina
- Durham VA Medical Center — Durham, North Carolina
- Edward Hines Jr. VA Hospital — Hines, Illinois
- George E. Wahlen VA Medical Center — Salt Lake City
- Joseph Maxwell Cleland Atlanta VA Medical Center — Decatur, Georgia
- Louis Stokes Cleveland VA Medical Center — Cleveland
- Michael E. DeBakey VA Medical Center — Houston
- Minneapolis VA Medical Center — Minneapolis
- Orlando VA Medical Center — Orlando, Florida
- Palo Alto VA Medical Center — Palo Alto, California
- Philadelphia VA Healthcare System — Philadelphia
- Portland VA Medical Center — Portland, Oregon
- Tibor Rubin VA Medical Center — Long Beach, California
- VA Greater Los Angeles Health Care System — Los Angeles
- VA North Texas Health Care System — Dallas
- VA Puget Sound Health Care System — Seattle
- William S. Middleton Memorial Veterans Hospital — Madison, Wisconsin
Alcohol Use Disorder Concerns Among Veterans
AUD, often known as alcoholism, refers to an impaired ability to stop or control alcohol consumption despite negative consequences. The VA references a study indicating 40.8% of veterans have met AUD diagnostic criteria at some stage, while more than 10.5% met criteria for probable AUD in the previous year. This condition is especially prevalent among younger veterans.
AUD may coincide with post-traumatic stress disorder (PTSD) and other mental health issues. Veterans with PTSD are twice as likely to experience alcohol problems compared to those without this history. Veterans showing signs of both AUD and PTSD deal with increased risks of depression, anxiety, and suicidal behavior. The VA supports concurrent treatment for both conditions through therapy, medication, or a combination of approaches.